Maravai LifeSciences Holdings, Inc. MRVI NASDAQ

Maravai LifeSciences Holdings, Inc. (MRVI) generated $-57.57M in operating cash flow for fiscal year 2025. After capital expenditures of $13.15M, free cash flow was $-70.72M.

Free cash flow margin was -38.1% of revenue. Cash conversion ratio was 0.44x, suggesting some earnings are non-cash.

Criteria supported by this page:

• HEALTH (67/100, Partial) — cash generation is adequate but may not fully cover debt in stressed conditions
• MOAT (21/100, Fail) — limited free cash flow weakens the competitive position
• INCOME (10/100) — Cash conversion ratio was 0.44x suggests some earnings are non-cash items

Overall SharesGrow Score: 43/100 with 2/7 criteria passed.